Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. New different pharmacological approaches to decrease inflammation of the airways and consequently disease progression and increase airway obstruction reversibility have been developed. In the present article, we review the new patents on phosphoinositide 3 kinase and NFκb inhibitors for future therapies.
Keywords: Alkylamines, azol-pyrimidines derivatives, chronic obstructive pulmonary disease, imidazolines, mTOR inhibitors, NFkb inhibitors, Phosphoinositide 3 kinase, quinazolines, triazoles, spirometry test, lipid kinases, oncogenes
open access plus
Rights & PermissionsPrintExport